Lysosomal dysfunction has emerged as a unifying pathological mechanism across multiple neurodegenerative diseases. While each disease has distinct primary protein pathologies, converging evidence demonstrates that impaired lysosomal enzyme activity represents a shared downstream pathway driving neuronal death[@nixon2024][@root2022].
This comparison examines how specific lysosomal enzymes — including cathepsins, glucocerebrosidase (GBA/GCase), acid alpha-glucosidase (GAA), and other hydrolases — contribute to disease pathogenesis across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).
Lysosomal dysfunction has emerged as a unifying pathological mechanism across multiple neurodegenerative diseases. While each disease has distinct primary protein pathologies, converging evidence demonstrates that impaired lysosomal enzyme activity represents a shared downstream pathway driving neuronal death[@nixon2024][@root2022].
This comparison examines how specific lysosomal enzymes — including cathepsins, glucocerebrosidase (GBA/GCase), acid alpha-glucosidase (GAA), and other hydrolases — contribute to disease pathogenesis across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).
| Enzyme | Gene | Function | AD | PD | ALS | FTD | HD | Key Reference |
|--------|------|----------|----|----|-----|-----|----|----|
| Cathepsin D | CTSD | Aspartyl protease; degrades Aβ, α-syn, tau | Deficient | Impaired | ↓ | Dysregulated | ↓ | [@bobe2019] |
| Cathepsin B | CTSB | Cysteine protease; hydrolyzes peptides | Elevated | Imbalanced | Altered | Imbalanced | Altered | [@nixon2024] |
| Cathepsin L | CTSL | Cysteine protease; protein turnover | Impaired | ↓ | Altered | Altered | ↓ | [@root2022] |
| Cathepsin S | CTSS | Cysteine protease; immune regulation | ↑ in microglia | Implicated | Unknown | Unknown | Unknown | [@lie2019] |
| Cathepsin A | CTSA | Serine protease; ganglioside metabolism | Implicated | Implicated | Unknown | Unknown | Unknown | [@nixon2024] |
| Glucocerebrosidase (GCase) | GBA1 | Cleaves glucosylceramide → glucose + ceramide | Reduced activity | Mutations ↑ risk 5–20× | Not primary | Not primary | Not primary | [@zhang2024] |
| Acid alpha-glucosidase (GAA) | GAA | Cleaves glycogen in lysosomes | Implicated | Not primary | Not primary | Not primary | Not primary | [@nixon2024] |
| Arylsulfatase A | ARSA | Cleaves sulfatides | Implicated | Not primary | Not primary | Not primary | Implicated (MLD) | [@lie2019] |
| Hexosaminidase A | HEXA | Cleaves GM2 gangliosides | Implicated (Tay-Sachs models) | Not primary | Not primary | Not primary | Not primary | [@nixon2024] |
| ATP13A2 (PARK9) | ATP13A2 | Lysosomal P5-type ATPase; polyamine transport | Impaired | Mutations → Kufor-Rakeb | Implicated | Implicated | Implicated | [@ren2022] |
| NPC1 | NPC1 | Cholesterol trafficking | Impaired | Not primary | Not primary | Not primary | Not primary (NPC2) | [@lie2019] |
| LAMP2 | LAMP2 | Lysosomal membrane protein; autophagy | Altered | Implicated (Danon) | Impaired | Impaired | Impaired | [@root2022] |
Lysosomal dysfunction in AD manifests through multiple interconnected pathways[@ad_lysosomal]. The accumulation of Aβ peptides within lysosomes causes lysosomal membrane permeabilization (LMP), leading to release of hydrolytic enzymes into the cytoplasm. Cathepsins B and D are elevated in AD brain tissue and contribute to tau hyperphosphorylation through activation of various kinases.
Key enzymes affected in AD:
PD demonstrates perhaps the strongest link between lysosomal enzyme dysfunction and disease pathogenesis[@pd_lysosomal]. Heterozygous GBA1 mutations (N370S, L444P, 84GG, RecNcil) are the most significant genetic risk factor for sporadic PD, increasing risk 5–20-fold depending on the specific variant[@zhang2024].
Key enzymes affected in PD:
ALS features prominent autophagy-lysosomal pathway dysfunction with multiple lysosomal enzymes affected[@als_lysosomal]. TDP-43 aggregates impair autophagy initiation through multiple mechanisms, including mTORC1 dysregulation and transcription factor inhibition.
Key enzymes affected in ALS:
FTD, particularly the GRN subtype, demonstrates direct lysosomal dysfunction as a primary disease mechanism[@ftd_lysosomal]. Progranulin (encoded by GRN) is a lysosomal enzyme that regulates cathepsin activity and lipid metabolism. GRN haploinsufficiency leads to cathepsin D and L dysregulation, resulting in TDP-43 pathology.
Key enzymes affected in FTD:
HD demonstrates autophagy impairment at multiple levels involving lysosomal enzymes[@hd_lysosomal]. Mutant huntingtin (mHTT) interacts with autophagy receptors (p62, NBR1), impairing cargo recognition and selective autophagy.
Key enzymes affected in HD:
| Trial | Phase | Disease | Target Enzyme | Intervention | Status | NCT |
|-------|-------|---------|--------------|--------------|--------|-----|
| Ambroxol PD Progression | Phase III | PD | GCase | Pharmacological chaperone | Recruiting | NCT05778617 |
| Ambroxol ASPro-PD | Phase 2/3 | PD | GCase | Pharmacological chaperone | Active | NCT05827068 |
| BIA 28-6156 | Phase 2 | PD (GBA+) | GCase | Small molecule chaperone | Recruiting | NCT05819359 |
| MRgFUS + GCase | Phase 1 | PD | GCase | Focused ultrasound + enzyme replacement | Recruiting | NCT05565443 |
| BIIB122 (LUMA) LRRK2i | Phase 2b | PD | LRRK2 (lysosomal trafficking) | LRRK2 kinase inhibitor | Active, not recruiting | NCT05348785 |
| Venglustat | Phase 2 | PD (GBA+) | GCase (substrate reduction) | Glucosylceramide synthase inhibitor | Stopped | NCT02947156 |
| AT3375 | Phase 1 | PD (GBA+) | GCase | Pharmacological chaperone | Phase 1 | — |
| LTI-291 | Phase 1 | PD | GCase activator | GCase activator | Phase 1 | — |
Ambroxol (NCT05778617): UCL-sponsored 330-participant Phase IIIa placebo-controlled trial, 104-week treatment duration. Primary endpoint: change in MDS-UPDRS Parts I–III. 12-month interim results showed sustained GCase activity increase and acceptable safety profile[@pd_gba_clinical].
BIA 28-6156 (NCT05819359): Bial Pharmaceutical Phase 2 trial specifically targeting GBA-mutation carriers with a novel oral small molecule GCase chaperone. Dose escalation with biomarker endpoints.
LUMA (NCT05348785): Biogen/Denali Phase 2b trial of BIIB122 (DNL151), a LRRK2 kinase inhibitor. 650 participants, primary endpoint time-to-confirmed worsening in MDS-UPDRS. LRRK2 inhibition restores normal lysosomal trafficking and TFEB activation.
| Target | Rationale | Therapeutic Approach | Clinical Stage |
|--------|-----------|---------------------|----------------|
| GBA/GCase | Restore enzyme activity, reduce glucosylceramide | Pharmacological chaperones (ambroxol, BIA 28-6156), gene therapy, substrate reduction | Phase 2/3 |
| Cathepsin D | Restore proteolytic balance | Small molecule modulators | Preclinical |
| TFEB activation | Promote lysosomal biogenesis | mTORC1 inhibitors, HDAC inhibitors, small molecule activators | Preclinical/clinical |
| V-ATPase | Restore lysosomal acidification | Small molecules, acidic nanoparticles | Preclinical |
| LAMP2 | Restore autophagy-lysosome fusion | Gene therapy, small molecule enhancers | Preclinical |
| ATP13A2 | Restore polyamine transport and pH | Gene therapy, small molecules | Preclinical |
| mTORC1 | De-repress autophagy initiation | Rapamycin, active-site inhibitors | Preclinical |
| Autophagy receptors | Enhance selective autophagy | TBK1 inhibitors, p62 modulators | Preclinical |
Several lysosomal storage diseases (LSDs) share pathological features with sporadic neurodegenerative diseases, providing insights into common mechanisms:
Gaucher Disease (GBA mutations): The most common LSD, caused by glucocerebrosidase deficiency. GBA mutations are the strongest genetic risk factor for PD (5-20x increased risk). Accumulation of glucosylceramide and glucosylsphingosine occurs. Parkinsonism develops in 5-10% of Gaucher patients, often before age 40.
Niemann-Pick Disease Type C: Involves cholesterol trafficking defects. NPC1 mutations associated with some AD cases. Lysosomal calcium dysregulation common to both NPC and neurodegeneration.
Farber Disease: Ceramide accumulation causes neurodegeneration, demonstrating the role of lipid metabolism in neuronal survival.
Common pathogenic mechanisms shared between LSDs and neurodegeneration:
| Enzyme | Normal Activity | Disease States | Measurement Method |
|--------|-----------------|----------------|-------------------|
| Cathepsin D | 100% baseline | AD: 40-60%, PD: 60-80% | Fluorometric assay |
| GCase (glucocerebrosidase) | 100% baseline | PD (GBA): 30-50% | Colorimetric |
| Cathepsin B | 100% baseline | AD: 50-70% | Fluorometric |
| Hexosaminidase | 100% baseline | Various LSDs | Colorimetric |
| Biomarker | Method | Disease Relevance |
|-----------|--------|-------------------|
| Cathepsin D activity | CSF enzymatic assay | AD, PD, FTD |
| GCase activity | Blood/Lyso-Gb1 | PD with GBA mutations |
| LAMP-1 | CSF ELISA | General lysosomal dysfunction |
| Autophagy markers (p62, LC3) | Blood Western blot | Monitoring autophagy induction |
| Lyso-Gb1 (glucosylsphingosine) | Blood | Sensitive for GBA carriers, correlates with PD risk |